KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Total Debt (2016 - 2026)

Pacira BioSciences has reported Total Debt over the past 15 years, most recently at $367.7 million for Q1 2026.

  • For Q1 2026, Total Debt rose 21.11% year-over-year to $367.7 million; the TTM value through Mar 2026 reached $367.7 million, up 21.11%, while the annual FY2025 figure was $372.2 million, 36.41% down from the prior year.
  • Total Debt for Q1 2026 was $367.7 million at Pacira BioSciences, down from $372.2 million in the prior quarter.
  • Over five years, Total Debt peaked at $585.3 million in Q4 2024 and troughed at $109.8 million in Q2 2024.
  • A 5-year average of $275.8 million and a median of $303.6 million in 2025 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: crashed 65.68% in 2023 and later surged 372.63% in 2024.
  • Year by year, Total Debt stood at $284.7 million in 2022, then tumbled by 56.5% to $123.8 million in 2023, then soared by 372.63% to $585.3 million in 2024, then tumbled by 36.41% to $372.2 million in 2025, then dropped by 1.22% to $367.7 million in 2026.
  • Business Quant data shows Total Debt for PCRX at $367.7 million in Q1 2026, $372.2 million in Q4 2025, and $376.7 million in Q3 2025.